Tag Archive | "johnson johnson"

Johnson & Johnson Loses Exec Committee Vice Chair

Johnson & Johnson Loses Exec Committee Vice Chair

Johnson & Johnson (NYSE:JNJ) has announced the resignation of Sheri S. McCoy, Vice Chairman of the Executive Committee.

Johnson & Johnson Loses Exec Committee Vice Chair

The US based Johnson & Johnson has said that Sheri S. McCoy, Vice Chairman of the Executive Committee, has resigned from the Company effective April 18 to join another publicly traded company as CEO.

William C. Weldon, Chairman and CEO of Johnson & Johnson (NYSE:JNJ) said, “Sheri has made important contributions across Johnson & Johnson (NYSE:JNJ) throughout her career. During these last several years, she was instrumental in helping to bring stronger strategic focus to our Pharmaceutical business as it builds a robust pipeline and launches important new medicines; and to our Consumer business as it leverages the success of its iconic brands and worked to resolve some recent challenges.”

Johnson & Johnson (NYSE:JNJ) shares were at 64.20 at the end of the last day’s trading. There’s been a 0.0% change in the stock price over the past 3 months.

Johnson & Johnson Loses Exec Committee Vice Chair
Johnson & Johnson (NYSE:JNJ) Analyst Advice
Consensus Opinion: Moderate Buy
Mean recommendation: 2
(1=Strong Buy, 5=Strong Sell)
3 Months Ago: 1.91
Zack’s Rank: 5 out of 14 in the industry

Posted in PharmaComments (0)

Johnson & Johnson Restarting Doxil Production

Johnson & Johnson Restarting Doxil Production

Johnson & Johnson (NYSE:JNJ) has decided to resume the production of cancer medicine, Doxil.

Johnson & Johnson Restarting Doxil Production

Johnson & Johnson (NYSE:JNJ) is working to take up the production of cancer medicine, Doxil, by September 2012 to increase the supply.

Due to a production quality issue, Doxil production at Boehringer Ingelheim’s Ben Venue Laboratories factory in Ohiowas stopped in November 2011.

Lisa Vaga, a spokeswoman for Johnson & Johnson (NYSE:JNJ) said,“Johnson & Johnson (NYSE:JNJ) may be able to boost its supplies of the drug sooner by having Ben Venue formulate the medication, then transfer it to another company for the filling and packaging of the product.”

Johnson & Johnson (NYSE:JNJ) stocks were at 64.92 at the end of the last day’s trading. There’s been a -0.1% change in the stock price over the past 3 months.

Johnson & Johnson Restarting Doxil Production
Johnson & Johnson (NYSE:JNJ) Analyst Advice
Consensus Opinion: Moderate Buy
Mean recommendation: 2
(1=Strong Buy, 5=Strong Sell)
3 Months Ago: 1.91
Zack’s Rank: 3 out of 14 in the industry

Posted in Headlines, PharmaComments (0)

Johnson & Johnson Makes US Tylenol Recall

Johnson & Johnson Makes US Tylenol Recall

Johnson & Johnson (NYSE:JNJ) has recalled Infant’s Tylenol in US due to bottle design problems.

Johnson & Johnson Makes US Tylenol Recall

The pharmaceutical company Johnson & Johnson (NYSE:JNJ) has recalled 574,000 bottles of grape-flavored, liquid Infant’s Tylenol from the US market due to complaints about its bottle design.

The company introduced Infant’s Tylenol three months ago claiming to have made big safety improvements to making measuring doses more accurate.

However, parents complained that when they inserted the syringe into the bottle, it also pushed the protective cover inside.

Johnson & Johnson (NYSE:JNJ) CEO William Weldon said, “Today’s news about the Infant’s Tylenol recall is clearly disappointing after all the progress that McNeil has been making to ensure its products meet the highest level of quality and consumer satisfaction”.

Johnson & Johnson (NYSE:JNJ) stocks were at 64.99 at the end of the last day’s trading. There’s been a 1.8% movement in the stock price over the past 3 months.

Johnson & Johnson Makes US Tylenol Recall
Johnson & Johnson (NYSE:JNJ) Analyst Advice
Consensus Opinion: Moderate Buy
Mean recommendation: 2
(1=Strong Buy, 5=Strong Sell)
3 Months Ago: 1.95
Zack’s Rank: 2 out of 14 in the industry

Posted in PharmaComments (0)

Johnson & Johnson (NYSE:JNJ) Making Leadership Changes

Johnson & Johnson (NYSE:JNJ) Making Leadership Changes

Johnson & Johnson (NYSE:JNJ) has made changes to its McNeil unit leadership.

Johnson & Johnson (NYSE:JNJ) Making Leadership Changes

The Wall Street Journal has reported that Johnson & Johnson (NYSE:JNJ) is replacing the chairman of its troubled McNeil Consumer Healthcare unit, which makes Tylenol and other OTC medicines.

The company has faced many recalls of its medicines produced by the McNeil unit.

The company will replace Patrick Mutcher, who was in charge of overseeing McNeil unit, with Roberto Marques.

Mutcher has been working in the company for more than 35 years.

Johnson & Johnson (NYSE:JNJ) is also replacing its chief strategist Pericles Stamatiades and he will leave the office by the end of March.

Johnson & Johnson (NYSE:JNJ) stocks are currently standing at 65.71.

Johnson & Johnson (NYSE:JNJ) Making Leadership Changes
Price History
Last Price: 65.71
52 Week Low / High: 57.5 / 68.05
50 Day Moving Average: 64.48
6 Month Price Change %: 1.2%
12 Month Price Change %: 8.0%

Posted in PharmaComments (0)

Johnson & Johnson (NYSE:JNJ) Wins Warning Lawsuit

Johnson & Johnson (NYSE:JNJ) Wins Warning Lawsuit

Johnson & Johnson (NYSE:JNJ) has won a lawsuit over its Levaquin warning.

Johnson & Johnson (NYSE:JNJ) Wins Warning Lawsuit

The pharmaceutical company Johnson & Johnson (NYSE:JNJ) has won a Minnesota jury verdict on the lawsuit filed by a patient saying that the company failed to give a warning about the risks of Levaquin.

The jury ruled that the company and its unit are not liable for the tendon injuries of the patient.

Bill Foster, Johnson & Johnson (NYSE:JNJ) spokesman, said, “The company is pleased with the verdict. When used according to the product labeling, Levaquin has been proven to be a safe and effective medication”.

Johnson & Johnson (NYSE:JNJ) shares are currently standing at 65.70.

Johnson & Johnson (NYSE:JNJ) Wins Warning Lawsuit
Price History
Last Price: 65.70
52 Week Low / High: 57.5 / 68.05
50 Day Moving Average: 64.45
6 Month Price Change %: 0.0%
12 Month Price Change %: 6.8%

Posted in PharmaComments (0)

Johnson & Johnson (NYSE:JNJ) Agrees To Huge Fraud Settlement

Johnson & Johnson (NYSE:JNJ) Agrees To Huge Fraud Settlement

Johnson & Johnson (NYSE:JNJ) has agreed to pay $158 million to settle a fraud case.

Johnson & Johnson (NYSE:JNJ) Agrees To Huge Fraud Settlement

The pharmaceutical company Johnson & Johnson (NYSE:JNJ) was ordered to pay $158 million to the state of Texas over a Medicaid fraud lawsuit.

The lawsuit said that the company’s subsidiary Janssen Pharmaceuticals promoted its Risperdal for off-label uses, and the company marketed the drug hiding its harmful side effects.

The drug was only approved for the treatment of adult schizophrenia.

Johnson & Johnson (NYSE:JNJ) also has to pay $258 million in Louisiana and $327 million in South Carolina on a Risperdal fraud case.

Johnson & Johnson (NYSE:JNJ) stocks are currently standing at 65.00.

Johnson & Johnson (NYSE:JNJ) Agrees To Huge Fraud Settlement
Price History
Last Price: 65.00
52 Week Low / High: 57.5 / 68.05
50 Day Moving Average: 64.4
6 Month Price Change %: -1.9%
12 Month Price Change %: 3.7%

Posted in PharmaComments (0)

Johnson & Johnson (NYSE:JNJ) To Launch Marketing Campagin

Johnson & Johnson (NYSE:JNJ) To Launch Marketing Campagin

Johnson & Johnson (NYSE:JNJ) has launched the ‘Hello me’ skin care marketing campaign.

Johnson & Johnson (NYSE:JNJ) To Launch Marketing Campagin

The pharmaceutical company Johnson & Johnson (NYSE:JNJ) has started a new marketing campaign ‘Hello me’ to promote its Skin Perfecting Oil.

The company said that the oil will help mothers to remove stretch marks in the body after having a baby. The campaign will run in healthcare press and women’s weekly magazines.

Johnson & Johnson (NYSE:JNJ)’s Body Care brand manager Hana Purchase said, “We are extremely excited to announce our latest product innovation, Skin Perfecting Oil, which marks a bold step change by the brand, moving into the stretch marks category for the first time. Our latest innovation does however stay true to Johnson’s equity, harnessing the trust the brand has built with new mums, whilst leveraging our heritage in soft skin”.

Johnson & Johnson (NYSE:JNJ) stocks are currently standing at 65.28.

Johnson & Johnson (NYSE:JNJ) To Launch Marketing Campagin
Price History
Last Price: 65.28
52 Week Low / High: 57.5 / 68.05
50 Day Moving Average: 64.33
6 Month Price Change %: -2.4%
12 Month Price Change %: 4.1%

Posted in PharmaComments (0)

Johnson & Johnson (NYSE:JNJ) Asks For Approval

Johnson & Johnson (NYSE:JNJ) Asks For Approval

Johnson & Johnson (NYSE:JNJ) has sought FDA approval for a third use for Xarelto.

Johnson & Johnson (NYSE:JNJ) Asks For Approval

Johnson & Johnson (NYSE:JNJ) has asked the US Food and Drug Administration to grant approval for using its anticlotting pill Xarelto or revaroxaban for patients with acute coronary syndrome.

Acute coronary syndrome is a condition of narrowing blood vessels reducing the blood flow to the heart muscles.

Xarelto was developed in partnership with Bayer HealthCare.

Johnson & Johnson (NYSE:JNJ)’s Xarelto has received approval for use in patients for preventing dangerous blood clots during knee or hip replacement and in patients with atrial fibrillation not caused by heart valve problem.

Johnson & Johnson (NYSE:JNJ) stocks were at 65.88 at the end of the last day’s trading. There’s been a 3.1% change in the stock price over the past 3 months.

Johnson & Johnson (NYSE:JNJ) Asks For Approval
Johnson & Johnson (NYSE:JNJ) Analyst Advice
Consensus Opinion: Moderate Buy
Mean recommendation: 1.91
(1=Strong Buy, 5=Strong Sell)
3 Months Ago: 2
Zack’s Rank: 2 out of 14 in the industry

Posted in PharmaComments (0)

More news from StocksAndShares.TV

Many meeting unexpected costs with instant loans
Investment boosts ahead for Egyptian economy
How to find the best credit card for you
Valero Energy Pauses Spot Gasoline Sales
Wal-Mart Wants Legal Case Rejection
Wells Fargo Signs Trade Finance Exec
AT&T To Sell Nokia In November
Microsoft Buys Authentication Tech Firm
Google Updates iOS Maps
Ford Launching New Ad Campaign

.
.